43.10 USD
▼-1.83-4.07%
盘后 47.50 0.00%
2026-09-15
市值
$2.95B
市盈率
—
EPS
-4.04
股息率
—
52 周区间
8.73 – 71.50
成交量
1.21M
Beta
0.94
目标价
69.65
52W 低 8.7352W 高 71.50
价格走势
公司简介
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ...